基于他克林和多奈哌齐的多靶向药物设计及其抗阿尔茨海默病活性研究进展

王柯人, 柳文敏, 桑志培

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (5) : 352-359.

PDF(1806 KB)
中国药学杂志
PDF(1806 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (5) : 352-359. DOI: 10.11669/cpj.2019.05.002
综述

基于他克林和多奈哌齐的多靶向药物设计及其抗阿尔茨海默病活性研究进展

  • 王柯人, 柳文敏, 桑志培*
作者信息 +

Progress of Multi-Target Directed Drugs Based on Tacrine and Donepezil in Alzheimer′s Disease

  • WANG Ke-ren, LIU Wen-min, SANG Zhi-pei*
Author information +
文章历史 +

摘要

阿尔茨海默病(Alzheimer′s disease,AD)是一种起病隐匿的进行性发展的神经系统退行性疾病。AD病因复杂,目前尚无有效的治疗方法。鉴于AD复杂的网络病理特征,能够同时作用于多个靶点的单一小分子化合物,即多靶向配体设计(multitarget-directed ligands, MTDLs)被认为是目前有效的治疗策略,其能与多个生物靶点上同时发挥作用,将大大有助于改善AD症状。笔者就近年来基于胆碱酯酶药效团、抗氧化、金属离子络合与神经保护剂等药效团的MTDLs新型候选药物进行了综述。

Abstract

Alzheimer′s disease (AD) is a progressive multifactorial neurodegenerative disorder in elder people. Currently, the pathogenesis of AD is unclear, and it is presently incurable. In view of the complex network pathological features of AD, a single small molecule compound that can act simultaneously with multiple targets, called multi-target directed ligands (MTDLs), is considered to be an effective therapeutic strategy at present. Here, we review highlights recent MTDLs approach based cholinesterase inhibitors, antioxidant, metal chelator and neuroprotectant in the novel drug candidate prototypes for the treatment of AD.

关键词

阿尔茨海默病 / 多靶点药物设计 / 多奈哌齐 / 他克林

Key words

Alzheimer′s disease / multi-target directed ligands / donepezil / tacrine

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
王柯人, 柳文敏, 桑志培. 基于他克林和多奈哌齐的多靶向药物设计及其抗阿尔茨海默病活性研究进展[J]. 中国药学杂志, 2019, 54(5): 352-359 https://doi.org/10.11669/cpj.2019.05.002
WANG Ke-ren, LIU Wen-min, SANG Zhi-pei. Progress of Multi-Target Directed Drugs Based on Tacrine and Donepezil in Alzheimer′s Disease[J]. Chinese Pharmaceutical Journal, 2019, 54(5): 352-359 https://doi.org/10.11669/cpj.2019.05.002
中图分类号： R914.2   

参考文献

[1] PRINCE M, WIMO A, GUERCHET M, et al. World Alzheimer Report 2015 The Global Impact of Dementia . Alzheimer's Disease International, 2015.
[2] ASHFORD J W. Treatment of Alzheimer's disease: the legacy of the cholinergic hypothesis, neuroplasticity, and future directions. J Alzheimers Dis, 2015, 47(1): 149-156.
[3] MOHAMED T, SHAKERI A, RAO P P, et al. Amyloid cascade in Alzheimer's disease: recent advances in medicinal chemistry. Eur J Med Chem, 2016, 113: 258-272.
[4] KORABECNY J, SPILOVSKA K, MEZEIOVA E, et al. Systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease. Curr Med Chem, 2018, doi: 10.2174/0929867325666180517094023.
[5] MILELLI A, DE SIMONE A, TICCHI N, et al. Tacrine-based multifunctional agents in Alzheimer's disease: an old story in continuous development. Curr Med Chem, 2017, 24(32): 3522-3546.
[6] KHOURY R, RAJAMANICKAM J, GROSSBERG G T, et al. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Ther Adv Drug Saf,2018, 9(3): 171-178.
[7] MONEIM A E. Oxidant/antioxidant imbalance and the risk of Alzheimer's disease. Curr Alzheimer Res, 2015, 12(4): 335-349.
[8] ADLARD P A, BUSH A I. Metals and Alzheimer's disease: how far have we come in the clinic . J Alzheimers Dis, 2018, 62(3): 1369-1379.
[9] SELLES M C, OLIVEIRA M M, FERREIRA S T. Brain inflammation connects cognitive and non-cognitive symptoms in Alzheimer's disease. J Alzheimers Dis, 2018, doi: 10.3233/JAD-179925.
[10] LIU K, LIN H H, PI R, et al. Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows. Expert Opin Ther Pat, 2018, 28(4): 341-350.
[11] DE FREITAS SILVA M, DIAS K S T, GONTIJO V S, et al. Multi-target directed drugs as a modern approach for drug design towards Alzheimer's disease: an update. Curr Med Chem, 2018, doi: 10.2174/0929867325666180111101843.
[12] CHEN L, FANG L, FANG X, et al. Progress of multi-target directed drugs based on AChE inhibitors in Alzheimer's disease. Chin Pharm J (中国药学杂志), 2010, 45(21): 1606-1611.
[13] ANAND P, SINGH B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res, 2013, 36: 375-399.
[14] XIE S S, WANG X, JIANG N, et al. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. Eur J Med Chem, 2015, 95:153-165.
[15] WANG X Q, XIA C L, CHEN S B, et al. Design, synthesis, and biological evaluation of 2-arylethenylquinoline derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2015, 89:349-361.
[16] FU Y, MU Y, LEI H, et al. Design, synthesis and evaluation of novel tacrine-ferulic acid hybrids as multifunctional drug candicates against Alzheimer's disease. Molecules, 2016, 21(10).pii: E1338.
[17] BENCHEKROUN M, ROMERO A, EGEA J, et al. The antioxidant additive approach for Alzheimer's disease therapy: new ferulic (lipoic) acid plus melatonin modified tacrines as cholinesterases inhibitors, direct antioxidants, and nuclear factor (erythroid-derived 2)-like 2 activators. J Med Chem, 2016, 59(21):9967-9973.
[18] CHIOUA M, PEREA-PENA J, GARCIA-FONT N, et al. Pyranopyrazolotacrines as nonneurotoxia Aβ-anti-aggregating and neuroprotective agents for Alzheimer's disease. Future Med Chem, 2015, 7(7):845-855.
[19] OSET-GASQUE M J, MARCO-CONTELLES J. New tacrines as anti-Alzheimer's disease agents. The (benzo)chromeno-pyranotacrines. Curr Top Med Chem, 2017, 17(31): 3349-3360.
[20] DERABLI C, BOUALIA I, ABDELWAHAB A B, et al. A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel tacrine-pyranopyrazole derivatives. Bioorg Med Chem Lett, 2018, pii: S0960-894X(18)30476-1.
[21] CZARNECKA K, CHUFAROVA N, HALCZUK K, et al. Tetrahydroacridine derivatives with dichloronicotinic acid moiety as attractive multipotent agents for Alzheimer's disease treatment. Eur J Med Chem, 2018, 145:760-769.
[22] CEN J, GUO H, HONG C, et al. Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity. Eur J Med Chem, 2018, 144:128-136.
[23] SPILOVSKA K, KORABECNY J, SEPSOVA V, et al. Novel tacrine-scutellarin hybrids as multipotent anti-Alzheimer's agents: design, synthesis and biological evaluation. Molecules, 2017, 22(6),pii: E1006.
[24] CHUFAROVA N, CZARNECKA K, SKIBINSKI R, et al. New tacrine-acridine hybrids as promising multifunctional drugs for potential treatment of Alzheimer's disease. Arch Pharm (Weinheim), 2018, 351(7):e1800050.
[25] CHIOUA M, BUZZI E, MORALEDA I, et al. Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. Eur J Med Chem, 2018, 155: 839-846.
[26] WU M T, ESTEBAN G, BROGI S, et al. Donepezil-like multifunctional agents: design, synthesis, molecular modeling and biological evaluation. Eur J Med Chem, 2016, 121: 864-879.
[27] GUZIOR N, BAJDA M, RAKOCZY J, et al. Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents. Bioorg Med Chem, 2015, 23 (7):1629-1637.
[28] WIECKOWSKA A, WIECKOWSKI K, BAJDA M, et al. Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorg Med Chem, 2015, 23 (10): 2445-2457.
[29] QIANG X, SANG Z, YUAN W, et al. Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease . Eur J Med Chem, 2014, 76 (1):314-331.
[30] DIAS K S, DE PAULA C T, DOS SANTOS T, et al. Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multi-target drugs for the treatment of Alzheimer's disease. Eur J Med Chem, 2017, 130: 440-457.
[31] SANG Z, PAN W, WANG K, et al. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2017, 130: 379-392.
[32] SANG Z, QIANG X, LI Y, et al. Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2015, 94: 348-366.
[33] SANG Z, QIANG X, LI Y, et al. Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2017, 135: 307-323.
[34] DIAS VIEGAS F P, DE FREITAS SILVA M, DIVINO DA ROCHA M, et al. Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: discovery of novel multi-target anti-alzheimer prototype drug candidates. Eur J Med Chem, 2018, 147: 48-65.
[35] HUANG W, WANG Y, LI J, et al. Design, synthesis and evaluation of genipin derivatives for the treatment of Alzheimer's disease. Chem Biol Drug Des, 2018, doi: 10.1111/cbdd.13194.
[36] CHIERRITO T P C, PEDERSOLI-MANTOANI S, ROCA C, et al. Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: potent butyrylcholinesterase inhibitors. Eur J Med Chem, 2018, 145: 431-444.
[37] CAI P, FANG S Q, YANG X L, et al. Rational design and multibiological profiling of novel donepezil-trolox hybrids against Alzheimer's disease, with cholinergic, antioxidant, neuroprotective, and cognition enhancing properties. ACS Chem Neurosci, 2017, 8(11): 2496-2511.
[38] VALENCIA M E, HERRERA AROZAMENA C, DE ANDRES L, et al. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. Eur J Med Chem, 2018, 156: 534-553.

基金

河南省高等学校重点科研项目资助(17B350002);南阳师范学院专项科研项目资助(ZX2016017)
PDF(1806 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉